CTLA-4 negatively regulates Treg cell activation against tumor-associated antigens (TAAs) by interacting with their ligands, B7.1 and B7.2, with higher affinity compared to CD28 binding to these ligands, and downregulates immune response against tumor [107]. This evidence concerns the gene CD86 and neoplasm.